Prostate Cancer Clinical Trial
Official title:
Phase 2 Clinical Trial to Evaluate Safety and Efficacy of BZ371A In A Gel Applied in Patients That Performed Radical Prostatectomy
To determine efficacy, safety and tolerabiltiy of topically applied BZ371A in patients that experienced RP, in combination with daily tadalafil compared to placebo.
Status | Recruiting |
Enrollment | 72 |
Est. completion date | September 2024 |
Est. primary completion date | August 2024 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 40 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Men between the ages of 40 and 65 years; 2. Exclusive heterosexual men, regardless of race or social class. 3. RP due to prostate cancer without metastasis; 4. RP performed less than 60 days before the screening visit; 5. Erectile function prior to normal RP, defined as IIEF questionnaire with more than 22 points in domain A; 6. Stable sexual partner (more than 2 months prior to RP), and intention to maintain the relationship during the study. 7. Continuous use of 5mg Tadalafil from the 30th up to the 60th day after RP. Exclusion Criteria: 1. Prostate cancer in TNM stage classified as T3 or T4. 2. Perineal and/or open RP; 3. Necessity of other therapy for prostate cancer than RP, including radiation therapy or hormone therapy; 4. Uncontrolled diabetes at screening visit (HbA1C > 10%); 5. Prior spinal cord injury with lower limb paralysis; 6. Current male hormone use, or hypogonadism, defined by total testosterone below 8 nmol/L (2300 pg/mL) or total testosterone between 8 and 11 nmol/L (2300 and 3170 pg/mL) and free testosterone < 220 pmol/L (< 64 ng/dL); 7. Patients with current depression, characterized by use or need for use of antidepressants. 8. Presence of genital lesions (such as severe penile fibrosis or Peyronie's disease) or active sexually transmitted disease (STD) (such as herpes, gonorrhea, candidiasis, HPV, and others) that impair analysis of local adverse effects on the genitalia; 9. Use of topical medications in the genital region that may interfere in the IP evaluation, as well as in its absorption or drug interaction; 10. Possession of penile prosthesis; 11. History of symptomatic hypotension, or diseases that increase the risk of symptomatic hypotension, such as patient with heart diseases (including history of angina and/or heart failure) and nephropathies; 12. Current use of nitrates, such as propatilnitrate (Sustrate®), isosorbide (Monocordil®, Cincordil®, Isordil®), nitroglycerin (Nitradisc®, Nitroderm TTS®, Nitronal®, Tridil®) and isosorbitol dinitrate (Isocord®);ketoconazole; ritonavir; and rifampicin. 13. Findings on ECG and/or laboratory tests that, in the Investigator's criteria, are considered significant and offer risk to the research volunteer's participation or may hinder the study analyses; 14. BP outside the limits considered safe: SBP below 90 mmHg or above 170 mmHg; or DBP below 50 mmHg or above 100 mmHg, except situations such as "white coat syndrome"; 15. Diseases that can cause priapism, such as sickle cell anemia, multiple myeloma, or leukemia; 16. Histroy of priapism, defined as painful erection from up to 6 hours. 17. Current relevant diarrhea, defined as duration over four weeks, association with abdominal pain or dysabsortive syndrome, or presence of mucus, pus, or blood in the stool; 18. Known hypersensitivity to tadalafil and/or BZ371A; 19. History of symptomatic Lactose intolorence such as: the necessity of enzymatic treatment, abdominal distension or diarrhea when ingesting products or supplements with lactose; 20. Low adhsesion to 5mg Tadalafil use, characterized by the use of <80% of the pills between the 30th and 60th day post PR;. 21. Pregnant or lacting partner. 22. Partner in childbearing age which does not accept to get exposed to the treatment 23. Any disease, condition or physical finding that the Investigator considers significant and that increases the risk of the research subject's participation or may interfere with the results, including severe debilitating illness, presence of cancer other than prostate cancer, severe mental illness persistent medication abuse; |
Country | Name | City | State |
---|---|---|---|
Brazil | Hospital Urológica | Belo Horizonte |
Lead Sponsor | Collaborator |
---|---|
Biozeus Biopharmaceutical S.A. |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Assisted Erectile Function | Measurement of the ability to to have an erection that allows sexual intercourse, under use of medication. This will be assessed by using the IIEF questionnaire, domain A (erectile function section) (IIEF-EF). | From up to 30 days before Baseline, Baseline, 30 days, 60 days | |
Secondary | Change in successful vaginal intercourse rate | Rate of successful vaginal intercourse will be assessed through question 3 of the SEP (Sexual Encouter Profile) questionnaire. | From up to 30 days before Baseline, Baseline, 30 days, 60 days | |
Secondary | Change in quality of sexual intercourse | Quality of sexual intercourse, through the EDITS questionnaire (Erectile Dysfunction Inventory of Treatment Satisfaction); | 30 days, 60 days | |
Secondary | Change in penile extension | Penile extension, measured with a ruler. | Baseline, 30 days, 60 days | |
Secondary | Penile Blood flow increase | Increased blood flow, assessed by peak systolic velocity (PSV), end-diastolic velocity (EDV) and resistivity index (RI) assessed by Doppler examination; | From up to 30 days before Baseline, Baseline, 30 days, 60 days | |
Secondary | Adverse effects report | Adverse effects evaluation of compound use and application | Baseline 30 days, 60 days and 75 days | |
Secondary | Physical examination of the applied region | Number of participants with abnormal physical exam findings in the applied region | From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days | |
Secondary | Change in SBP | Change in Systolic Blood Pressure | From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days | |
Secondary | Change in DBP | Change in Diastolic Blood Pressure | From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days | |
Secondary | Change in Heart Rate (HR) | Change in Heart Rate | From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days | |
Secondary | Basal chest electrocardiogram (ECG). | Number of participants with abnormal ECG test results | From up to 30 days before Baseline, 30 days and 60 days | |
Secondary | Blood evaluation | Number of participants with abnormal laboratory test results | From up to 30 days before Baseline, and 60 days | |
Secondary | Urine evaluation | Number of participants with abnormal laboratory test results | From up to 30 days before Baseline, and 60 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |